Allison Schneider, MPH, provides a detailed update regarding pharmacies’ impact within Medicare price negotiations and the legislation further impacting businesses.
|Articles|January 10, 2005
New biologic offers hope for MS patients
According to the National Multiple Sclerosis Society, an estimated 10,000 new cases of multiple sclerosis are diagnosed every year. The most common form of MS at the time of diagnosis is the relapsing-remitting form, in which acute signs and symptoms occur intermittently and will go into intermission either spontaneously or with steroid therapy.
Advertisement
Advertisement
Related to this article
The US health department announced policies that will allow for the compounding of 6 key peptides in US pharmacies.
New survey data add to the evidence regarding the safe and effective route of administering both COVID-19 and flu vaccines simultaneously.
This episode breaks down how PBMs conduct inventory audits, the sourcing and timing issues that trigger recoupments, and how pharmacies can prepare and push back.
In part 2 of our discussion with Kimberly Kue-Tsemo, PharmD, she addresses the emergence of technology and the nuances behind its actual capabilities.
In part 2, Allison Schneider, MPH, discusses PBM and 340B reform that could compound pharmacies’ burden amid ongoing Medicare drug price negotiations.
Researchers provide an update on the adverse events of special interest following patients who received 2024–2025 Pfizer-BioNTech COVID-19 vaccination.
Type 1 and type 2 diabetes reports emphasize areas where pharmacists can act now, including CGM, cardio-kidney therapies, and equitable patient access.
Advertisement
Advertisement
Trending on Drug Topics
1
HHS Lets Pharmacies Compound Peptides as FDA Writes Official Rule
2
Updated Diabetes Consensus Shifts Focus from Glucose Control to Whole-Person Care
3
American Pharmacists Month: Pharmacy Deserts Growing in US Despite Rising Awareness
4
Future IRA Drug Negotiations Expected to Compound Pharmacy Burden
5